Table 2.
Hidden platform test change in path length (in m) in an ovariectomized mouse model of Alzheimer’s disease
| Group | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 |
|---|---|---|---|---|---|
| Control | 7.77±1.09 | 6.14±0.31 | 5.97±0.33 | 5.89±0.44 | 5.59±0.26 |
| VPA | 7.01±0.78 | 5.75±0.26 | 4.98±0.27 | 3.33±0.22** | 3.75±0.28 |
| E2 | 5.33±1.01** | 3.67±0.34** | 3.24±0.40** | 2.10±0.34**** | 2.13±0.42**** |
| LG | 6.88±0.98 | 5.82±0.13 | 4.59±0.43 | 3.51±0.51** | 2.70±0.19*** |
| VPA+E2 | 5.76±0.36* | 4.85±0.26 | 3.35±0.43** | 2.69±0.12**** | 2.14±0.10**** |
| VPA+LG | 6.67±0.29 | 4.22±0.41* | 2.90±0.31*** | 2.04±0.35**** | 1.66±0.25**** |
Data are presented as the mean ± SEM (n = 8). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, vs. control group (two-way analysis of variance with Student-Newman-Keuls tests). E2: 17β-Estradiol; LG: liquiritigenin; VPA: valproic acid.